Venous thromboembolic events in pancreatic carcinoma patients
Not Applicable
- Conditions
- Treatment naive pancreatic carcinoma patients
- Registration Number
- JPRN-UMIN000009474
- Lead Sponsor
- ational Cancer Center Hosipital Hepato-bilialy and pancreatic Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 103
Inclusion Criteria
Not provided
Exclusion Criteria
past history of VTE taking an anticoagulant
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the likelihood of VTE
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link KRAS mutations to venous thromboembolism in treatment-naive pancreatic carcinoma patients?
How does the incidence of VTE in early-stage vs. advanced pancreatic cancer compare in observational studies?
Which biomarkers correlate with venous thromboembolic risk in pancreatic carcinoma patients according to the NCCH-009 study?
What are the management strategies for VTE in pancreatic cancer patients observed at the National Cancer Center Hospital?
Are anticoagulants like LMWH effective in preventing VTE in pancreatic carcinoma patients undergoing standard care?